DOLUTEGRAVIR SODIUM
| Brand name | TIVICAY |
|---|---|
| Active ingredient | DOLUTEGRAVIR SODIUM |
| Strength | EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | June 2016 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 9242986*PED | June 2030 | — |
| 9242986 | December 2029 | substance, product |
| 8129385*PED | April 2028 | — |
| 8129385 | October 2027 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.